Juno Diagnostics Announces Closing Of $25 Million Series A Financing Led By Perceptive Xontogeny Venture Fund
Juno Diagnostics Announces Closing Of $25 Million Series A Financing Led By Perceptive Xontogeny Venture Fund
05/12/21, 10:59 AM
Location
san diegoRound Type
series a
Juno Diagnostics (JunoDx), a company focused on improving access to vital genetic health information and led by industry experts, announced today the closing of an expanded Series A financing round of $25 million led by the Perceptive Xontogeny Venture (PXV) Fund. The capital will be used to support clinical validation studies, product development, and commercial launch of JunoDx’s product offerings for noninvasive prenatal testing (NIPT).
Company Info
Location
san diego, california, united states
Additional Info
Juno Diagnostics is developing genetic testing solutions to improve access to vital health information. The Company’s lead product is an NIPT solution that simplifies sample collection and improves access to high quality genetic testing results without the high cost, long lead times, and phlebotomy requirements of traditional NIPT. The founding team worked together at Sequenom, Inc., pioneering the development and commercialization of the first noninvasive cell-free DNA based prenatal test in the United States. For more information, visit www.junodx.com.